In the past few months, we have all been confronted with an entirely new situation. Our patients belong to the high-risk group by definition. Hospitals, outpatient clinics, and medical practices have had to be restructured and reorganize their priorities. Workflows had to be re-examined with regard to factual and time-related aspects with hygiene in mind. The goal has been to ensure continued care for patients, while at the same time protecting the employees trained for that very purpose.
Over the past few years, the use of targeted therapies has proven effective for various forms of hematological neoplasia, and increasingly become routine. The rational molecular design of such active substances allows for the targeted blocking of intracellular signal chains in malignant cells, resulting e.g. in cell cycle arrest or ideally apoptosis. Unfortunately, resistance occurs even against such tailored therapies.
Thanks to the rapid advancement of sequencing technology, it has become easier to read an increasingly large amount of DNA. However, the ability to interpret this data has not grown by the same amount. For this purpose, high-performance computer clusters are necessary in order to analyze the large quantities of data for a standard next-generation sequencing (NGS) run. After the initial positive experiences with cloud computing as part of the 5.000 genome projekt, we decided to switch to cloud computing for the evaluation of the NGS routine diagnostics data as well.
In this digital age, MLL has now set up a way to enter orders online. Following an extensive beta testing phase in the outpatient area, it is now possible to use a corresponding digital platform free of charge.
